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Oncogenic mink cell focus-forming (MCF) viruses, such as MCF 247, show a positive correlation between the
ability to replicate efficiently in the thymus and a leukemogenic phenotype. Other MCF viruses, such as MCF
30-2, replicate to high titers in thymocytes and do not accelerate the onset of leukemia. We used these two MCF
viruses with different biological phenotypes to distinguish the effect of specific viral genes and genetic
determinants on thymotropism and leukemogenicity. Our goal was to identify the viral sequences that
distinguish thymotropic, nonleukemogenic viruses such as MCF 30-2 from thymotropic, leukemogenic viruses
such as MCF 247. We cloned MCF 30-2, compared the genetic hallmarks of MCF 30-2 with those of MCF 247,
constructed a series of recombinants, and tested the ability of the recombinant viruses to replicate in the thymus
and to induce leukemia. The results established that (i) MCF 30-2 and MCF 247 differ in the numbers of copies
of the enhancer sequences in the long terminal repeats. (ii) The thymotropic phenotype of both viruses is
independent of the number of copies of the enhancer sequences. (iii) The oncogenic phenotype of MCF 247 is
correlated with the presence in the virus of duplicated enhancer sequences or with the presence of an enhancer
with a specific sequence. These results show that the pathogenic phenotypes of MCF viruses are dissociable
from the thymotropic phenotype and depend, at least in part, upon the enhancer sequences. On the basis of
these results, we suggest that the molecular mechanisms by which the enhancer sequences determine
thymotropism are different from those that determine oncogenicity.
Mink cell focus-forming (MCF) retroviruses have been
implicated as the proximal leukemogenic agents in the in-
duction of spontaneous leukemia in certain inbred strains of
mice (19, 21, 23, 34). MCF viruses have been isolated from
the thymus and other tissues of AKR mice during the
preleukemic period (9, 10, 15, 16). Some MCF isolates when
injected into newborn animals accelerate the onset of leuke-
mia (10, 34). The ability to replicate to high titers in the
thymus and express high levels of murine leukemia virus
(MuLV)-related cell surface antigens on infected thymocytes
is tightly correlated with the oncogenic phenotype of this
class of MCF viruses (20, 28, 36, 37). MCF 247 is the
prototype of thymotropic, oncogenic MCF viral isolates
(23-25, 34).
MCF viruses with biological phenotypes distinct from
those of MCF 247 have been isolated from thymocytes of
preleukemic AKR mice (36, 37). These viruses are unique
because they replicate to high titer and express MuLV-
related cell surface antigens on infected thymocytes and do
not accelerate the onset of leukemia in AKR mice. MCF 30-2
is the prototype of this class of MCF viruses (37). Since
previous studies showed that the ability of MCF as well as
radiation-induced MuLV to replicate in thymocytes is posi-
tively correlated with the leukemogenic phenotype (10, 11),
the isolation of this class of viruses presents a paradox. We
were interested in this paradox and have used MCF 30-2 as
the prototype of this group of exceptional viruses to define
the genetic determinants which distinguish it from MCF 247.
Studies using MCF 247, Friend, and Moloney MuLVs, as
well as a number of other viruses have demonstrated that
* Corresponding author.
MuLV enhancer elements, present as duplicated sequences
within the long terminal repeats (LTRs) of these viruses, are
important to the tissue tropism and oncogenic properties of
these viruses (3-6, 12-14, 17, 24, 32, 33, 43, 46, 52). To
determine whether these or other sequences determine the
difference in the oncogenic phenotypes of MCF 247 and
MCF 30-2, we have cloned MCF 30-2, compared the viral
genomes of MCF 30-2 and MCF 247, and constructed and
characterized a set of recombinants between MCF 247 and
MCF 30-2. We show here that the major differences between
MCF 30-2 and MCF 247 are in the pl5E region of the env
gene and in the LTR. In addition, we demonstrate that the
differential virulence of MCF 30-2 and MCF 247 is due to
sequences in the LTR.
MATERIALS AND METHODS
Molecular cloning of MCF 30-2. Hirt extracts of two
separate cultures of Mus dunni cells infected with MCF 30-2
virus were prepared, and molecular clones were isolated as
described previously (25). Briefly, viral DNA was digested
with EcoRI and cloned into pBR322. Clones were identified
by hybridization to 32P-labeled DNA from a molecular clone
of MCF 247. Inserts from 10 clones were isolated, concate-
nated, and transfected into SC-1 or M. dunni cells (22, 31).
Medium from separate cultures transfected with 3 of the 10
molecular clones (p30-2-C1128-1, p30-2-1464-1, and p30-
2-1464-8A) contains retroviral reverse transcriptase activity
(1). Two of the clones (p30-2-1464-1 and p30-2-1464-8A)
were derived from a single Hirt extract, and the third
(p30-2-C1128-1) was cloned from a separate infection. One
clone, p30-2-1464-8A, was used to generate the site-specific
recombinant viruses described below. The three clones of
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MCF 30-2 were mapped by digestion with 12 restriction
enzymes (PstI, KpnI, SmaI, PvuI, PvuII, HindIll, Sau3A,
XhoI, ClaI, HpaI, EcoRI, and XbaI).
Construction of recombinants. Recombinants were con-
structed as described previously (25). Restriction sites used
to generate recombinants were conserved in both MCF 30-2
and MCF 247 (7, 8). The structures of the recombinants were
verified by using unique restriction sites diagnostic for the
fragments present in recombinants. MCF 247 has a unique
EcoRI site in the LTR (7, 8). This site is not present in the
LTR of MCF 30-2 (data not shown). The structures of the
recombinant viruses produced after transfection of the
clones were confirmed by digesting viral intermediates with
EcoRI and analyzing the digest with a Southern blot. All
recombinants with an LTR of MCF 247 consistently con-
tained an EcoRI site, whereas the site was absent from
recombinants with an MCF 30-2 LTR. In some cases, the
structures of the recombinants were confirmed by analyzing
RNase T1 fingerprints of viruses produced after transfection
of the recombinants. The fingerprints were analyzed for the
presence or absence of the unique MCF 247 or MCF 30-2
RNase Tl-resistant oligonucleotides in the precursor to the
piSE gene (PrplSE gene) (29, 34).
Two independent clones of MCF 247 were used to gener-
ate the recombinants. One, p247-W, produced infectious
virus when transfected into M. dunni cells as described
previously (25). Another molecular clone of MCF 247 (p247-
lb) did not produce infectious virus when transfected. The
LTR of p247-lb was biologically functional when used to
generate an infectious recombinant and has been sequenced
(29).
Viruses and viral assays. Infectious viruses were generated
from the DNA constructs of parental viruses or recombi-
nants after DNA transfection into M. dunni cells. These cells
are permissive for the replication of MCF viruses (31). The
presence of infectious virus in culture supernatants was
assayed by the S+L- assay on mink cells or by the presence
of reverse transcriptase activity (1).
RNase T1 fingerprints. Preparation of 32P-labeled viral
RNA, its digestion with RNase T1, and separation of the
resulting oligonucleotides by two-dimensional gel electro-
phoresis were performed as described previously (18).
DNA sequencing. All DNA sequencing was performed as
previously described, using M13mpl8 or M13mpl9 vectors
(35).
Pathogenicity tests. Female AKR/J mice (40 to 45 days of
age) were anesthetized by intraperitoneal injection of aver-
tine (aqueous solution of 0.29 mg of 2,2,2,-tribromoethanol-
160 mg of isoamyl alcohol per g of body weight). The thymus
was exposed surgically as described previously (27), and the
left lobe was injected with virus or tissue culture medium as
a control (0.05 ml per lobe normalized to 500 to 1,000 pmol
per ml of reverse transcriptase activity, representing approx-
imately 5 x 104 infectious units). Injected mice were ob-
served for signs of frank leukemia (scruffled fur, hunched
appearance with chest enlargement, labored breathing,
lymph node enlargement). Induction of thymic lymphoma
was confirmed by gross pathologic examination of affected
tissues at necropsy. In some experiments, virus-injected
mice were not observed after 180 days of age, at which time
the incidence of spontaneous leukemia in AKR/J control
mice becomes significant (24, 37, 38).
RESULTS
Characterization of molecular clones of MCF 30-2. To
define the viral genes that distinguish MCF 247 from MCF
30-2, the genomes of the viruses were compared by RNase
T1 fingerprinting and restriction mapping. We used these
techniques to reveal significant differences between the two
viruses. Shown in Fig. 1 are RNase T1 fingerprints of the
viruses produced after transfection of the molecular clones
of MCF 247 (p247-W) and MCF 30-2 (p30-2-1464-8A). The
two viruses share all commonly analyzed oligonucleotides
localized to the sequences encoding gp7O and the LTR.
Isolated, unique oligonucleotides are present in both MCF
247 and MCF 30-2 (i.e., 30-2B, 107, and 29; Fig. 1A and B).
Since these unique oligonucleotides are in separate genes, it
is most likely that they represent single-base changes in the
viral genomes. Conversely, a major oligonucleotide substi-
tution was located in the pi5E region of the envelope gene
(Fig. 1E). Two oligonucleotides that are present in the pl5E
gene of MCF 30-2 (i.e., 30-2A and 119) are missing in MCF
247 and are replaced by three other oligonucleotides (i.e., 18,
33, and 47; Fig. 1E).
To determine whether the oligonucleotide substitutions in
the pl5E gene represent major amino acid differences in the
gene products of MCF 30-2 and MCF 247, the DNA se-
quence of the pi5E gene of MCF 30-2 was determined and
compared with that of MCF 247 (29; Fig. 2A). The nucleo-
tide sequences of the pi5E genes of MCF 247 and MCF 30-2
differ by 9.3% (56 differences in a total of 603 nucleotides;
Fig. 2A). Third-base changes account for 6% of the differ-
ences. The predicted amino acid sequences of the proteins
differ by -5% (10 amino acid differences in 201 amino acids).
Therefore, the oligonucleotide differences in the pl5E genes
of MCF 30-2 and MCF 247 reflect a series of single-
amino-acid differences in the two proteins.
To extend the results of the RNase T1 oligonucleotide
mapping, the molecular clones of MCF 247 and MCF 30-2
were compared by restriction mapping. Differences in three
restriction sites were found between clones of MCF 30-2 and
MCF 247. A HpaI site located in the gag region and an
EcoRI site in the LTR of MCF 247 were missing in MCF 30-2
(data not shown). In addition, three infectious molecular
clones of MCF 30-2 were digested with PstI and KpnI. The
double digest of the three clones of MCF 30-2 produced a
fragment derived from each LTR that was approximately 100
nucleotides smaller than the same fragment derived from a
clone of MCF 247 (p247-W).
To define the structure of the MCF 30-2 LTR, the LTR of
MCF 30-2 was sequenced and compared with the sequences
of two clones of MCF 247. Shown in Fig. 2B are the LTR
sequences of two molecular clones of MCF 247 (p247-W and
p247-1b) and a clone of MCF 30-2 (p30-2-1464-8A). The
sequences of the two clones of MCF 247 are identical except
that one contains two copies of a sequence present as a
direct repeat in p247-W, whereas the second (p247-1b)
contains a single copy of this sequence. The LTR of MCF
30-2 has one copy of the enhancer sequence that is dupli-
cated in MCF 247 (p247-W) as well as four other nucleotide
sequence differences. The enhancer sequence of MCF 30-2
is identical to the second copy of the enhancer of one clone
of MCF 247 (p247-W) and has a single-nucleotide sequence
difference with the other clone of MCF 247 (p247-1b).
Together, the RNase T1 fingerprints and DNA sequencing
results show that the major differences that distinguish MCF
247 and MCF 30-2 lie in the plSE region of the env gene and
in the LTR.
Two separate experiments suggest that the original MCF
30-2 virus contained a single copy of the duplicated enhancer
sequence of MCF 247. First, the restriction mapping data
showed that each of the three clones of MCF 30-2 had a
VOL. 63, 1989 1285
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FIG. 1. (A through D) RNase T1 fingerprints of MCF 247 and MCF 30-2. Viral RNAs obtained after transfection of the molecular clones
of MCF 247 or MCF 30-2 were analyzed by RNase T, digestion and two-dimensional gel electrophoresis. Panels A and B are schematic
diagrams of the T1 fingerprints shown in panels C and D and were traced from those fingerprints. The numbers assigned to specific
oligonucleotides are according to Rommelaere et al. (42). RNase T1 oligonucleotides specific for MCF 30-2 are identified (30-2A and 30-2B).
The RNase T1 oligonucleotides that are enclosed in solid lines in panels A and B are shared by both MCF 247 and MCF 30-2. The putative
positions of oligonucleotides absent from a particular fingerprint are indicated by a broken line. (E) Schematic representation of the genomic
location of large RNase T1-resistant oligonucleotides of MCF 30-2 and MCF 247. The box is a schematic diagram of a retroviral genome.
Specific viral genes (gag, pol, gp7O, and Prp15E) as well as regions of the LTR (U3, R, and US) are shown. Sites of cleavage of restriction
enzymes are indicated (Sst, SstII; Xa, XbaI; P, PstI). The numbers and locations of RNase T1-resistant oligonucleotides unique to either MCF
30-2 or MCF 247 and shared by both are shown. The locations of the oligonucleotides were determined either by DNA sequencing or T1
oligonucleotide mapping (29, 42). Oligonucleotides that have not been localized by either method are indicated in parenthesis (i.e., 30-2B and
107).
single copy of the enhancer sequence. These three clones
were derived from two separate infections of M. dunni cells.
It is therefore more likely that the original virus had a single
copy of the enhancer sequence. Second, a Southern blot
analysis of viral circular DNA intermediates isolated 16 h
after infection ofM. dunni cells with MCF 30-2 virus showed
that the DNA contained one copy of the enhancer sequences
(data not shown). Taken together, these data suggest that the
original viral stock ofMCF 30-2 was homogeneous and most
viral genomes contained a single copy of the enhancer
sequences.
Leukemogenicity of MCF 30-2 and MCF 247 recombinants.
To evaluate the effect of differences in the pl5E genes and
LTRs of MCF 247 and MCF 30-2 on the ability to accelerate
leukemia, a series of molecular recombinants was con-
structed (Fig. 3). Restriction enzyme sites located in identi-
cal positions in both viral genomes were identified. We used
those sites to exchange between clones of MCF 247 and
MCF 30-2 a fragment from XbaI to PstI which encodes 80%
of the pl5E gene and 37 nucleotides of the U3 region of the
LTRs (recombinants 1 and 2, Fig. 3). There are no nucleo-
tide sequence differences between the viruses in the LTR
portion of the XbaI-to-PstI fragment. In addition, greater
than 95% of the amino acid differences in the pl5E genes of
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MCF247W protein Glu Pro Val Ser Leu
MCF247W gene GAA CCC GTC TCA CTA
MCF30-2 gene *** *** *** *** ***
MCF30-2 protein *** *** *** *** ***
MCF247W protein Gly Thr Gly Thr Thr
MCF247W gene GGA ACA GGG ACT ACC
MCF30-2 gene *** *** *** *** ***
MCF30-2 protein *** *** *** *** ***
MCF247W protein Leu Lys Glu Val Glu
MCF247W gene CTT AAA GAA GTT GAA
MCF30-2 gene *** *** *** *** ***
MCF30-2 protein *** *** *** *** ***
MCF247W protein Gln Asn Arg Arg Gly
MCF247W gene CAG AAT CGT AGA GGC
MCF30-2gene *** *** *** *** ***
MCF30-2 protein *** *** *** *** ***
MCF247W protein Cys Cys Phe Tyr Ala
MCF247W gene TGC TGT TTC TAT GCC
MCF30-2 gene *** *** *** *** A
MCF30-2 protein *** ** *** * ***
MCF247W protein Gln
MCF247W gene CAG
MCF30-2 gene ***
MCF 30-2 protein ***
Thr Leu Ala Leu
ACT CTG GCC CTA
Ala Leu Val Ala
GCC CTA GTG GCC
Asp His Thr Gly Leu
GAC CAC ACA GGA TTG
*** *** **T **C G*A
*** *** *** *** Val
Arg Gln Lys Leu Phe Glu Ser Gln Gln
AGA CAA AAG CTC TTT GAA TCC CAA CAA
**G *** **A T*G **C *** **A GG* ***
*** *** **S **S *** *** Gly ***
MCF247W protein Thr Thr Leu Ile Ser Thr
MCF247W gene ACC ACC CTG ATA TCC ACC
MCF30-2 gene **G ** ** 5** *** **
MCF30-2 protein *** *** *** ** *** *
MCF247W protein Ile Leu Asn Arg Leu Val
MCF247W gene ATT CTC AAT CGC CTG GTC
MCF30-2 gene *** *** **C * T*A **
MCF30-2 protein *** *** **** *** **
MCF247W protein Gln Tyr His Gln Leu Lys
MCF247W gene CAG TAT CAC CAA CTC AAA
MCF30-2gene *** *** *** *** **
MCF30-2 protein *** *** ** ***
Ile Met Gly Pro
ATC ATG GGT CCC
**T ** C **T
Gln Phe Val Lys
CAG TTT GTA AAA
Ser Ile Asp Pro
TCA ATA GAT CCA
*5* 5** 5***
55* *** *** ***
Leu Leu Gly Gly Leu Thr Met Gly Gly Ile Ala Ala Gly Val
CTA TTA GGA GGA CTC ACT ATG GGC GGA ATT GCC GCT GGA GTA
*** *** *** *** *** *** *** *** *** *** *** *** *** **G
*** *** 5** *** *** *** *** 5** 555 *** 555 *** 5** ***
Gln Phe Gln Ala Ala Met Gln Asp Asp
CAA TTC CAG GCT GCC ATG CAG GAT GAC
*** C** *** *** *** G** **C *** ***
*** Leu *** *** *** Val His *** ***
Val Arg Asp Ser Met Ala Lys Leu Arg Glu Arg Leu Ser
GTA CGG GAT AGC ATG GCC AAA CTT AGA GAA AGA TTG AGT
A** *** * T **G **A * ** **G C*A *AC
*** * ***** *** *** *** *** *** Asn
Gly Trp Phe Glu Gly Leu Phe Asn Lys Ser Pro Trp Phe
GGG TGG TTT GAA GGG CTG TTT AAT AAG TCC CCT TGG TTC
**T *** **G A*A * * **C *G* *** **A* ***
*** ** *** *** Arg * ** *** Arg *** ***
Leu Ile Ile Leu Leu Leu Ile Leu Leu Phe Gly Pro Cys
CTG ATA ATC CTC TTG TTA ATT TTA CTC TTT GGG CCT TGT
* G*A **T **A * **C C** C*C **A **C **C
*** *** Val *** *** *** *** Leu *** *** ***
Asp Arg Ile Ser Val Val Gln Ala Leu Val Leu Thr Gln
GAC AGA ATT TCG GTG GTG CAG GCC CTG GTT CTG ACC CAA
*** *** *** *** *** *** *** *** *** ***
*** *** *** *** *** *** *** *** *** *** *** S**
Glu Glu Val Glu Ser Arg Glu
GAA GAA GTA GAA TCG CGT GAA TAA
555
*** *** ***
555
***
re-U3
BMCF247W TGAAAGACCCCACCATAAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTTTGCAAGGCATGAAAAAGTACCAGAGCTGAATTCTCAAAAGBMCF2471b *********************************************
MCF30-2 *********************************************
MCF247W TCACAAGGAAGTTTAGTTAAAGAATAAGGCTGAACAAAACTGGGACAGGGIGCCAAACAGGATATCTGTGGTCGAGCACCTGGGCCCCGGC
MCF2471b ****** ****** ********************
---------------------------------------
MCF30-2 *******.******************-------------------------
MCF247W TCAGGGCCAAGAACAGATGGTACTCAGATAAAGCGAAACTAGCAACAGTTTTGGAGAGTCCACCCTTCACCAAACAGGATATCTGTGGT
MCF2471b
----------------------------------------------------------------------**
MCF30-2
---------------------------------------------------------------------- * *
MCF247W CGAGCACCTGGGCCCCGGCTCAGGGCCAAGAACAGATAGTACTCAGATAAAGCGAAACTAGCAACAGTTTGGAAAGTCCCAAGTMCF2471b ****SSS*S*S*SSS5S*******55S ** **6 *55*5* *
MCF30-2 ************************************G**************************************************
M CF247W nTCAAGTTcCCCAAAAGACCGGGAAAAAcCCCAAGCCTTATTTAAACTAACCAATCAGCTCGCTTCTCGCTTCTGTAACCGCGCTTTATG
MCF2471b *********** ****************
MCF30-2 **********************A* * * * * * * * * * * *
R
MCF247W CTCCCCAGCCCTATAAAAAGGGTAAAAACCCCACACTCGcIGCGCCAGTCCTCCGATAGACTGAGTCGCCCGGGTACCCGTGTATCCAAT
MCF2471b ************* ********************SS***S******************* 55* *****
MCF30-2 * ******** ***** ************************************
U5
MCF247VV AAAGCCTTTTGCTGTTGCAifCCGAATCGTGGTCTCGCTGATCCTTGGGAGGGTCTCCTCAGAGTGATTGACTGCCCAGCCTGGGGGTCTTMCF2471b **************************************ses*******************************************
MCF30-2 ****************A************************************************************************
MCF247W TCA
MCF2471b a**s
MCF30-2
FIG. 2. Nucleotide sequences of the pl5E genes and the LTRs of MCF 247 and MCF 30-2. (A) The nucleotide and predicted amino acid
sequences of the pl5E envelope gene of MCF 30-2 were determined and compared with those of MCF 247 (29). (B) The LTR sequences of
separate clones ofMCF 247 (p247-W) and MCF 30-2 were determined and compared with those published previously (29) for a clone ofMCF
247 (p247-1b). *, Nucleotide sequences or amino acids identical to those shown on the top line. Nucleotide sequence differences are indicated.
Dashes indicate the absence of a nucleotide. 4, Sequences present as a direct repeat in MCF 247-W. Boxes enclose a site with homology
to the simian virus 40 enhancer core identified in Moloney MuLV as the binding site for NF-KB (45, 48).
VOL. 63, 1989
Thr Gln Gln Phe Gln
ACT CAG CAG TTC CAA
5** *** 5** *** 555
5*5 *** *** *ee ***
Lys Ser Ile Thr Asn Leu Glu Lys Ser Leu Thr Ser Leu Ser Glu Val Val Leu
AAG TCC ATC ACT AAT CTA GAA AAA TCT TTG ACC TCC TTG TCC GAA GTA GTG TTA
555 *** *** *ee *** *** 555 *** *** *** 555 *** *** 555 *** *** *** ***
*** *** *** *** *** *** 5** *** 55* *** *** *** *** 555 55* *** *** ***
Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly Leu Cys Ala Ala Leu Lys Glu Glu
CTA GAT CTA CTA TTC CTA AAA GAG GGA GGT TTG TGT GCT GCC TTA AAA GAA GAA
*** *** **G **G *** *** *** **A *** **A **A *** *** *** C** *** *** ***
*** *** *** *** *** *** *** *** 5** *** *** *** *** 5** *** *** 5** ***
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___________________________________Sequencing data shown in Fig. 2B establishes that the LTR
909ga pot I gp7O 115EjL-TR] of one clone of MCF 247 (p247-1b) is identical to another
I I I ~~~~~~~~~~(p247-W) except that the second contains two copies of the
S Xo P direct repeat (p247-W). We considered these clones as
variants and have used these two clones of MCF 247 to
assess the importance of the number of copies of the
enhancer sequences. In addition, since both MCF 247 clones
-~~~ differ from MCF 30-2 in other LTR sequences, we used these
MCF 247 variants to assess the importance of those nudle-
otide sequence differences as well (see Fig. 2B).
__________________________________2 Viruses obtained after transfection of the molecular clonesI lIE2
~~~~~~~~~~~ofMCF 247, MCF 30-2, and the recombinants shown in Fig.
3 were injected intrathymically into 45-day-old AKR mice.
__________________________________Leukemogenicity of the viruses was evaluated by determin-{03 ~~ing the percentage of animals that developed thymic lym-
phoma by 180 days of age (Fig. 4, Table 1). After 180 days,
] control mice injected with media developed tumors sponta-
r 4
~~~~~~~~~~~neously (Fig. 4a) and 90% of the animals died from thymic
lymphoma by 300 days of age. Nearly 100% of the animals
-______________________________injected with virus derived from transfection of the molecu-
5 lar clone of MCF 247 developed tumors by 180 days of age
compared with 7% of the mice injected with MCF 30-
2-derived virus. The recombinant composed predominantly
6 of MCF 247 but with the pl5E region of MCF 30-2 (recom-
.1 ~~~~~~~~~~~~~binant1, Fig. 3 and Fig. 4b) accelerated leukemia almost as
rapidly as MCF 247. Moreover, the MCF 247 piSE region
did not significantly change the nonleukemogenic phenotype
p247-W of MCF 30-2 (recombinant 2, Fig. 3 and Fig. 4b). Thus, the
-------p247- lbdifferences in the piSE genes of MCF 30-2 and MCF 247
.p247-lb ~~~~(Fig. 2A) are not sufficient to explain the differences in their
- p30-2 pathogenicity.
j. 3. Viral genomes of recombinants. Schematic representa- The results obtained by injecting recombinants containing
of molecular recombinants. Restriction sites shared by DNA different LTRs (Fig. 3, recombinants 3, 4, 5, and 6) were
ofMCF247andMCF30- wee ued o gnerte ecobi- quite different. The LTR of MCF 30-2 dampened the ability
(P, Pstl; 5; SstII; Xa, Xbal) and are shown at the top relative of MCF 247 to accelerate leukemia (Fig. 4, recombinant 3).
retroviral genome. Sequences were derived from one of two Conversely, the LTR of MCF 247 made MCF 30-2 a more
,s of MCF 247 or from a clone of MCF 30-2 (~, p30-2). One leukemogenic virus (Fig. 4, recombinant 4). These data
of MCF 247 contains two copies of the enhancer-containing suggest that the LTR of MCF 247 is the major determinant of
mIces (-~,p247-W); a second clone of MCF 247 contains one the difference in the leukemogenic potential of these two
,p247-1b). Molecular recombinants are numbered. MCF viruses. We noted that the incidence of leukemia at 180
days of recombinant 4 (Table 1; 75%) was lower than that for
247 and 30-2 are contained on this XbaI-to-PstI frag- MCF 247 itself (Table 1; 90%). In addition, the latent period
t.Thus, recombinants 1 and 2 effectively exchange the of recombinant 4 (Table 1; 170 ±+ 35) was longer than that of
sequence differences shown in Fig. 2. MCF 247 (Table 1; 127 ±+ 32). These results imply that there
evaluate the effect of the MCF 30-2 and MCF 247 LTRs are other viral sequences in addition to the LTR that differ
hymotropism and pathogenesis, we exchanged a frag- between MCF 247 and MCF 30-2 and contribute, at least in
tbetween the PstI and SstII sites of MCF 247 and MCF part, to the leukemogenic phenotypes of the viruses.
(Fig. 3, recombinants 3, 4, 5, and 6). The fragment We noted that the clone of MCF 247 (p247-W) used to
ains most of the LTRs of the viruses and the 5' noncod- donate the LTR to recombinant 4 contained two copies of
-egion of the viral genome, including the primer-binding the enhancer sequences (Fig. 2B). To determine whether the
and a portion of the coding region of two gag genes (p15 difference in leukemogenic potential of MCF 247 and MCF
p12). The PstI-to-SstII fragment was obtained from each 30-2 was due to the presence of two copies of the enhancer
vo clones of MCF 247. The sequences of the LTRs of sequences in the MCF 247 LTR relative to the single copy in
, two clones are shown in Fig. 2B. One, p247-W, the MCF 30-2 LTR, we constructed recombinant S (Fig. 3).
ains two copies of the enhancer sequences present as a Recombinant S is identical to recombinant 4, except that the
At repeat. The second, p247-lb contains a single copy of PstI-to-SstII fragment of the recombinant used to replace the
sequence. In addition., since MCF 247 contains an LTR of MCF 30-2 was obtained from a molecular clone of
)nucleotide (i.e., 107; Fig. 1A) absent from MCF 30-2, MCF 247 (p247-1b) with a single copy of the enhancer. As a
.iucleotide sequences of the genomes of MCF 30-2 and control, the same fragment was attached to the genome of
7247 between the end of the LTR and the Sstll site were MCF 247 obtained from p247-W (recombinant 6). Each of
rmined and compared. The leader regions of the ge- these was tested for the ability to accelerate the onset of
es have three isolated nucleotide sequence differences, leukemia. The incidence of leukemia at 180 days in animals
~he amino acids of the gag genes of the two viruses are injected with recombinant 6 was considerably lower (Table
tical (data not shown). Thus, the major difference be- 1; 35%) than the incidence for MCF 247 itself (Table 1; 90%).
,n the two viruses in the PstI-to-SstII fragment is the These data show that the nucleotide sequence differences
J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 5, 2008 
jvi.asm.org
D
ow
nloaded from
 
EFFECT OF ENHANCER SEQUENCES ON LEUKEMIA ACCELERATION
80
w
Li.
0
w
z
w
0
z
60
40
20
80
60
40
20L >
100 200 100 200
DAYS OF AGE
FIG. 4. Incidence of leukemia in AKR/J mice after intrathymic injection of parental and recombinant viruses. (a) The development of
leukemia in mice injected with MCF 247W (0) or MCF 30-2 (O) virus is compared with the incidence of leukemia in control mice injected
with media (A). (b) The incidences of leukemia in mice injected with parental viruses (MCF 247W [0]; MCF 30-2 [l]) are compared with
those for viruses with recombinant pl5E genes. Recombinant 1 contains the pl5E gene derived from MCF 30-2 (0). Recombinant 2 expresses
the MCF 247W pl5E gene (U). (c and d) The leukemogenic potential of recombinant viruses with different LTRs is shown. Recombinant 3
(@) and recombinant 4 (U) have an MCF 30-2 and an MCF 247-W LTR, respectively. (d) Recombinant 6 (0) has an LTR derived from MCF
247-lb. Recombinant 5 has the same LTR as recombinant 6, but the structural genes are derived from MCF 30-2 (U). The data in panel a and
in panels b, c, and d were derived from separate experiments. The numbers of mice in each group are given in Table 1.
between MCF 247-lb and MCF 247 (Fig. 2B) dramatically
reduce the leukemogenic potential of MCF 247. In addition,
the recombinant composed of MCF 30-2 but with the MCF
247 LTR with one copy of the enhancer (recombinant 5)
produced approximately the same incidence of leukemia at
180 days (Table 1; 9%) as MCF 30-2 itself (Table 1; 7%).
These data suggest (i) that the nucleotide sequence differ-
ences in the LTRs of MCF 30-2 and one of the clones of
MCF 247 (p247-ib) do not dramatically affect the leuke-
mogenic phenotypes of the viruses and (ii) that the presence
of the duplicated enhancer sequences of MCF 247 (p247-W)
contributes to the ability of this virus to accelerate leukemia.
The enhancer-containing sequences of the two parental
clones of MCF 247 (p247-W and p247-1b) were aligned with
those of MCF 30-2 (Fig. 5). We sequenced and compared the
first copy of the direct repeat of MCF 247-W with that of the
second as well as with those of MCF 247-lb and MCF 30-2.
There are four nucleotide sequence differences among the
enhancer sequences. The first copy of the direct repeat in
MCF 247-W has a nucleotide transition (A to G). This
transition occurs in the sequence which in Moloney MuLV
binds the B-cell-specific enhancer-binding protein NF-KB
(45, 48). In addition, the first direct repeat of MCF 247-W has
three additional nucleotides compared with the second copy
TABLE 1. Acceleration of leukemia in AKR/J mice injected with recombinant and MCF viruses
Virus (no.') Structure (Diseased mice)/ Latent Incidence of(injected mice)' periodc leukemia (%)d
MCF 247-W 9/10 127 + 32 90
MCF 30-2 1/15 148 7
1 IZ 3 14/14 137 ± 24 100
2 °2 2/15 180 13
3 3/21 165 ± 16 14
4 ° °4 15/20 170 ± 35 75
5 1]---l H 2/22 163 ± 11 9
6 I --16 7/20 170 ± 12 35
aNumbers refer to genomes of viruses generated after transfection of molecular clones diagrammed in Fig. 3.
b The number of mice with disease is compared with the total number of mice injected with a specific virus.
The latent period was calculated as the mean of all animals observed with disease at less than 180 days ± standard error.
d Calculated as (number of mice with disease at <180 days)/(number of mice injected) x 100.
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1 drMCF 247W CCAAACAGGATATCTGTGGTCGAGCACCTGGGCCGGCTCAGGGCCAAGAACAGATGGTACTCAGATAAAGCGAAACTAGCAACAGTT IGGAGAGTCCrACCCTTC
2drMCF247W.
MCF2471b.
MCF30-2.
FIG. 5. Nucleotide sequences of enhancers of MCF viruses. The duplicated repeat region of the leukemogenic virus MCF 247W is
compared with the single copy present in the clones of MCF 247-lb and MCF 30-2.
of the direct repeat in MCF 247-W. The second copy of the
direct repeat in MCF 247-W is identical to that of MCF
247-lb and MCF 30-2. Our data does not exclude the
possibility that these nucleotide sequence differences in the
enhancer sequences contribute to the leukemogenic pheno-
type of MCF 247.
Thymotropism of the molecular recombinants. Studies on
avian leukosis viruses demonstrate that the U3 region of the
LTR is an important determinant of the growth rate of avian
leukosis virus in fibroblasts (41, 49). More recent studies
demonstrate that the LTR functions to determine the leuke-
mogenic potential of the viruses in vivo by mediating the rate
of infection of the bursal target stem cell (2). The timing of
infection of thymocytes appears to affect the acceleration of
leukemia in AKR mice as well (16).
To determine whether the number of copies of the en-
hancer sequence affects the ability of MCF viruses to
replicate in thymocytes, we quantitated and compared the
number of infectious viral particles produced by thymocytes
isolated from animals 48 days after injection with either
MCF 30-2, MCF 247, or recombinant viruses. Since the
assay for thymotropism was performed 48 days after in-
trathymic injection of the viruses, we recognize that the
viruses or the recombinants might replicate to different titers
early after injection. Figure 6 shows that MCF 30-2, MCF
247, and most of the recombinant viruses were thymotropic
as measured by infectious center assay on S+L- mink cells.
The only possible exception was recombinant 5 (30-2 + 247
lb LTR). Thymocytes isolated from three animals injected
with recombinant 5 produced a low titer of virus. Thymo-
cytes isolated from a fourth animal from that group produced
a titer of virus approximately equal to that of the parents or
other recombinants. We conclude from these data that MCF
30-2, MCF 247, and all the recombinants, including recom-
binant 5, are thymotropic.
In all cases, the frequency of infectious centers in thymo-
cyte suspensions was low (0.01 to 0.1%), yet no infectious
centers were detected in thymuses of control mice injected
with tissue culture medium (<0.1/106 thymocytes). Despite
the low level of productive infection, flow cytometric anal-
ysis of thymocytes stained with a monoclonal antibody that
reacts with both ecotropic and MCF MuLV gp7os showed
that, on the average, 64% of thymocytes expressed high
levels of gp7O compared with thymocytes of control mice.
The majority of thymocytes in MCF 30-2, MCF 247, and
recombinant virus-injected mice were, in fact, infected at
day 48 as judged by expression of viral antigen, a known
characteristic of MuLV-infected lymphoid cells (19, 20, 36,
37). These data confirm previous reports which demonstrate
that the viral phenotypes of thymotropism and pathogenicity
are clearly separable (37). In the present work, we have
demonstrated that oncogenicity is dependent on the number
of copies of the retroviral enhancer sequences or on their
specific sequences.
DISCUSSION
Evidence from studies of several retroviruses supports the
hypothesis that the ability of a virus to replicate in the target
tissue as well as the transformation potential of MuLVs are
both controlled, at least in part, by sequences within the
retroviral LTR (3, 5, 6, 12-14, 17, 24, 32, 33, 43, 46, 52). The
results of experiments presented here demonstrate that the
enhancer sequences of MCF viruses are important determi-
nants of the disease-inducing potential in these viruses.
These studies extend previous reports demonstrating that
the LTR of MCF 247 controls an in vitro tissue culture host
range property of the virus that is correlated with the in vivo
thymotropic phenotype (25). Specifically, these data show
that a single copy of the enhancer sequence is sufficient to
establish the thymotropic phenotype of MCF 30-2 and that
two copies of the enhancer or a specific enhancer sequence
are required for an MCF virus to accelerate the onset of
leukemia in AKR mice. Although the isolation of a leuke-
mogenic MCF virus (MCF 13-81) with a nonduplicated
enhancer has been reported (26), the sequence of the en-
hancer of MCF 13-81 differs from that of MCF 30-2 and the
number of enhancers in the viruses found in tumors have not
been examined.
The hypothesis that two copies of the enhancer are an
essential feature of a leukemogenic virus is supported by the
recent finding that spontaneous tumors ofAKR mice contain
viruses with duplicated enhancer sequences even though the
identified endogenous virus which is the U3 donor for
leukemogenic MCF viruses (BXV-1) contains a single copy
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FIG. 6. Thymotropism of parental and recombinant viruses in
AKR/J mice. The number of infectious centers per 106 thymocytes
was scored in an S+L- mink focus induction assay. Thymocytes
were obtained from animals at 48 days after intrathymic injection
with medium, a virus to serve as a positive control (MCF 69L1),
parental (MCF 247W or MCF 30-2), or recombinant viruses (recom-
binant 1, 247W + 30-2 pl5E; recombinant 2, 30-2 + 247W pl5E;
recombinant 3, 247W + 30-2 LTR; recombinant 4, 30-2 + 247W
LTR; recombinant 6, 247W + 2471b LTR; recombinant 5, 30-2 +
2471b LTR). Virus injections were normalized with respect to
reverse transcriptase activity.
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of the enhancer (J. Stoye, C. Moroni, and J. Coffin, personal
communication). These data argue that two copies of the
enhancer sequences are functionally important to the molec-
ular mechanism of transformation by MCF viruses.
The presence of two copies of the enhancer sequences in
the virus which is the proximal leukemogenic agent in AKR
mice might influence the transformation process at a variety
of levels and may be important to achieve high levels of
either viral or cellular gene transcription. A direct effect on
viral transcription may result in an increase either in the
number of infected target cells or in the number of integrated
proviruses per cell. Alternatively, the presence of two copies
of the enhancer sequence creates a unique DNA sequence at
the junction of the 3' end of the first copy of the enhancer
and the 5' end of the second copy. This DNA sequence is
unique and could be used as a new binding site for a
trans-acting protein. Evidence for the existence of multiple,
cooperative, or overlapping protein-binding sequences in the
enhancer elements of Moloney (48) and Friend (N. Manley,
P. Sharpe, and N. Hopkins, personal communication)
MuLV, Rous sarcoma virus (30), simian virus 40 (39, 53),
and polyomavirus have been presented previously (40, 44,
50).
The number of enhancer sequences produces differential
effects in MuLVs with distinct oncogenic or tissue tropic
properties. It has been demonstrated that Friend or Moloney
MuLV with one copy of the enhancer sequence induces
disease with a longer latent period compared with viruses
with two copies of the enhancer (17, 33, 47). Conversely,
separate experiments show that neither the number of copies
nor the exact sequence of the enhancer determines either the
latent period or the tissue specificity of spleen focus-forming
virus (SFFV) (51). Neither the disease specificity nor the
latency of the disease was affected by the number of copies
of the direct repeat or by the origin of the direct repeat (from
Friend MuLV, Friend MCF, or Moloney MuLV). These
experiments and others suggest that the env gene of SFFV is
the primary determinant of the leukemogenicity of SFFV
(51). Taken together with our data, these results suggests
that MCF viruses and some other replication-competent
retroviruses transform the target cell by a different mecha-
nism than that of SFFV. The mechanism of transformation
of the replication-competent retroviruses might be depen-
dent on a specific enhancer-controlled function, whereas
viral genes of SFFV and other oncogene-containing replica-
tion-defective viruses transform the target cell more directly.
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